お知らせ • Jan 27
Deep Medicine Acquisition Corp. Approves the Election of Directors On January 19, 2024, Deep Medicine Acquisition Corp. held a special meeting of its stockholders approved the election of Christopher Jones, Shaun Limbers, AJ Redmer and Riley Russell as Directors. お知らせ • Feb 18
Deep Medicine Acquisition Announces Listing Transfer to the Nasdaq Capital Market Deep Medicine Acquisition Corp. (the “Company”) announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its securities from the Nasdaq Global Market to the Nasdaq Capital Market. The Company's Class A common stock and rights will continue to trade under the symbol “DMAQ” and “DMAQR,” respectively and trading of its Class A common stock and rights will be unaffected by this transfer. This transfer will be effective as of the opening of business on February 17, 2023. As previously disclosed, the Company received a letter from Nasdaq on January 22, 2023 indicating that the Company, following the stockholder redemptions at its last stockholder meeting, is not in compliance with Listing Rule 5450(b)(2), due to the Company’s failure to meet the minimum 1,100,000 publicly held shares requirement for continued listing on the Nasdaq Global Market. Upon the transfer of listing of the Company's securities on the Nasdaq Capital Market on February 17, 2023, such deficiency would be resolved. お知らせ • Jan 28
Deep Medicine Acquisition Receives Non-Compliance Notice Form Nasdaq On January 22, 2023, Deep Medicine Acquisition Corp. received a written notice (the Notice") from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq") indicating that, following the stockholder redemptions at the Company's last stockholder meeting, the Company is not in compliance with Listing Rule 5450(b)(2), due to the Company's failure to meet the minimum 1,100,000 publicly held shares requirement for continued listing on the Nasdaq Global Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market. The Notice states that the Company has until March 9, 2023 to submit a plan to regain compliance with Listing Rule 5450(b)(2). The Company is exploring all options to regain compliance with Listing Rule 5450(b)(2). The Company intends to submit a plan to regain compliance with Listing Rule 5450(b)(2) within the required timeframe. If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Notice to evidence compliance with Listing Rule 5450(b)(2). If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal the decision in front of a Nasdaq Hearings Panel. お知らせ • Nov 23
Deep Medicine Acquisition Corp., Annual General Meeting, Dec 23, 2022 Deep Medicine Acquisition Corp., Annual General Meeting, Dec 23, 2022. お知らせ • Oct 25
Deep Medicine Acquisition Corp. Appoints John Chiang as Member to its Board of Directors Deep Medicine Acquisition Corp. announced the appointment of Mr. John Chiang as a member to its board of directors, effective October 15, 2022. Mr. Chiang has been serving as a member of the board of directors of Apollo Medical Holdings Inc. since January 2019 and on the corporate advisory boards of Pasadena Private Lending, LLC since February 2019, Adept Urban since January 2021, and Calyx Peak Companies since February 2019. From January 2015 to January 2019, Mr. Chiang served as the California State Treasurer, where he oversaw financial transactions, investments and the sale of bonds. Prior to that, Mr. Chiang served as California State Controller from January 2007 to January 2015. お知らせ • Jul 14
Chijet Inc. entered into a definitive business combination agreement to acquire Deep Medicine Acquisition Corp. (NasdaqGM:DMAQ) in a reverse merger transaction. Chijet Inc. entered into a definitive business combination agreement to acquire Deep Medicine Acquisition Corp. (NasdaqGM:DMAQ) in a reverse merger transaction on July 12, 2022. Business combination agreement with Deep Medicine Acquisition Corp. values Chijet’s operating companies at $2.55 billion (based on 100% ownership). In the proposed transaction, both Chijet and DMAQ will be acquired by a newly-formed holding company named Chijet Motor Company, Inc. (“Pubco”), which is expected to be listed on the Nasdaq Stock Market (“Nasdaq”). Each of the DMAQ's issued and outstanding shares of Class A Common Stock will be cancelled in exchange for the right of the holder thereof to receive one ordinary share, par value $0.0001 per share, of Pubco. Hongwei Mu, Chairman of Chijet, and the existing leadership team will lead the combined company. The boards of directors of DMAQ and Chijet have unanimously approved the proposed transaction. Its closing is subject to approval by DMAQ stockholders, completion of DMAQ’s satisfactory due diligence review of Chijet within 60 days of entering into the business combination agreement and is subject to other customary closing conditions, including the U.S. Securities and Exchange Commission (“SEC”) declaring Pubco’s registration statement effective and the expiration of the applicable HSR Act waiting period. It is currently expected that the transaction will close by the end of the fourth quarter of 2022, assuming such closing conditions are met.